Navigation Links
Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection

enging setting."

Preclinical studies suggest that Valortim has the potential to provide significant protection against anthrax infection when administered prophylactically (prior to the emergence of symptoms of anthrax infection) and also may increase survival when administered therapeutically (once symptoms become evident). In these studies, Valortim has been shown to protect both rabbits and monkeys against the lethal effects of anthrax infection when administered at the time of exposure, at doses as low as 1.0 mg/kg. When administered to rabbits after the development of symptoms, Valortim also improved survival as late as 48 hours post-exposure as compared to controls.

"We believe that there are distinct characteristics of Valortim that make it an ideal choice for military and civilian protection against an anthrax bioterrorist attack," commented David P. Wright, President and Chief Executive Officer of PharmAthene. "As our Phase I results have demonstrated, a single intramuscular dose of Valortim produces levels of antibodies in humans that correspond to protective levels in animal models and is well tolerated. Based on the impressive human safety and animal efficacy data collected to date, we believe that Valortim could meet the needs of the U.S. Government and could ultimately be selected for inclusion in the Strategic National Stockpile to provide protection to the American public."

About Valortim

Valortim (MDX-1303) is a fully human antibody designed to protect against anthrax infection, including inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium. The investigational antibody is designed to target a protein component known as the anthrax protective antigen (PA) of the lethal toxin complex produced by the bacterium. The anthrax protective antigen is believed to initiate the onset of the illness by attaching to cells in the infected person, and then is believed to facilitate the
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Cethromycin Shown Effective Against Anthrax in Study
3. Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax Infection
4. Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO
5. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
6. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal Models
9. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial
Post Your Comments:
(Date:8/27/2014)... 27, 2014 Reportlinker.com announces that a ... catalogue: Global Orthopedic Soft Tissue Repair ... About Orthopedic Soft Tissue ... of cells that connect, support, or surround bones. ... such as tendons, ligaments, cartilage, fascia, and other ...
(Date:8/27/2014)...  Decision Resources Group finds that physicians surveyed ... gastroenterology, endocrinology and nephrology) expect the robustness and ... been assessed in to be the strongest influencers ... Other key findings from the ... of Biosimilars Across Physician Specialties : ...
(Date:8/27/2014)... Mass. , Aug. 27, 2014 Decision ... that characterized the Memphis health ... way to clinical integration, with rivals Methodist Le Bonheur ... respective physician groups to coordinate patient care. In addition, ... which has the most health plan enrollment in the ...
Breaking Medicine Technology:Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 3Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 5Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials 2Memphis-area Health Systems Turn Attention to Clinical Integration 2
... 2011 Centre Partners Management LLC ("Centre Partners"), a leading ... and Los Angeles, today announced the completion of the sale ... Troy Limited (Nasdaq: HELE). Kaz is an international leader in ... valued at $260 million subject to certain closing working capital ...
... The MED Group, a Managed Health Care Associates, Inc. ...  The website was created to help answer questions for ... about competitive bidding and how patients can receive their ... Centers for Medicare and Medicaid Services (CMS) will be ...
Cached Medicine Technology:Centre Partners Announces Successful Realization of Investment in Kaz, Inc. 2Centre Partners Announces Successful Realization of Investment in Kaz, Inc. 3New Program for Medicare Beneficiaries Will Mean Major Changes Effective January 1, 2011 - Florida 2New Program for Medicare Beneficiaries Will Mean Major Changes Effective January 1, 2011 - Florida 3
(Date:8/27/2014)... of hormone therapy has spawned a prevalent but preventable ... hot flashes, according to a study by a Yale ... the study published in the Aug. 27 online issue ... that moderate to severe hot flashes also called ... women. Women with VMS experience more than feeling hot; ...
(Date:8/27/2014)... (PDT, which uses topical agents and light to kill ... common skin lesion caused by sun damage) at three ... to freeze lesions). , Author: Gayatri Patel, ... Center, in Sacramento, and colleagues. , Background: ... found on individuals with fair complexions who have had ...
(Date:8/27/2014)... Michigan Head & Neck Institute is hosting a school ... school by ensuring they have everything they need for a ... Michigan Head & Neck Institute wants to ensure the children ... "There are a lot of military families in the area, ... back to our community," said Lauren Taylor, Marketing Coordinator at ...
(Date:8/27/2014)... Dr. Stewart Shofner and Dr. Kevin ... suffering from impaired vision. Some of the most common ... . Recently, Dr. Shofner has noticed a significant increase ... and also online. To help patients understand the facts, ... , 1)    Myth: People with perfect vision won’t develop glaucoma. ...
(Date:8/27/2014)... Washington, New York (PRWEB) August 27, 2014 ... dedicated to protecting the rights of victims injured by ... new rules in place for discovery procedures, specifically Collection ... brought over C.R. Bard’s transvaginal mesh devices. (MDL No. ... Products Liability Litigation, the United States District Court, Southern ...
Breaking Medicine News(10 mins):Health News:The high cost of hot flashes: Millions in lost wages preventable 2Health News:Photodynamic therapy vs. cryotherapy for actinic keratoses 2Health News:Michigan Head & Neck Institute is Conducting Their 2nd Annual School Supplies Drive at Their Facility to Benefit Local Year-Round Elementary School Students 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 4Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 2Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 4
... Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today ... Third Quarter 2007 Results For the quarter ... of $734,347 or $0.06 loss per basic and diluted ... loss per basic and diluted share for the,same period ...
... Nov. 14 (HealthDay News) -- A protein that may have ... be a biomarker that indicates severe asthma. And it may ... to new research. , Reporting in the Nov. 15 issue ... University researchers said that people with severe asthma were more ...
... aim . . . , As the ... a high performance bullet based on technology developed at ... precision and superior terminal ballistics and is lead-free and ... Wakeman, Ohio, the technology is first being made available ...
... Reason for their added survival remains unclear, scientists say ... Hispanics appear to live longer following an Alzheimer,s diagnosis ... men and women of Asian and American Indian descent ... expectancies equivalent to that of white Alzheimer,s patients, ...
... December 31, RICHARDSON, Texas, Nov. 14 Blue ... will offer three Medicare Part D,prescription drug plans with ... Medicare beneficiaries in Texas can sign up,for or switch ... open enrollment period, which begins November 15 and continues ...
... Inc. announced today that CC Detect(SM), the ... now available from Panacea,Laboratories. CC Detect(SM) is ... identification of individuals with cancer of the ... standard screening methods. Panacea Laboratories,a division of ...
Cached Medicine News:Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 2Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 3Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 4Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 5Health News:Defensive Protein Linked to Asthma 2Health News:Defensive Protein Linked to Asthma 3Health News:Story tips from the Department of Energy's Oak Ridge National Laboratory, Nov. 2007 2Health News:Blacks, Hispanics Live Longer With Alzheimer's 2Health News:Blacks, Hispanics Live Longer With Alzheimer's 3Health News:Blacks, Hispanics Live Longer With Alzheimer's 4Health News:Blue Cross and Blue Shield of Texas Announces Flexible, Affordable Blue MedicareRx(SM) Medicare Prescription Drug Plans 2Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 2Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 3Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 4Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: